SCHEMBL31723977

SCHEMBL31723977

NC(=O)C(C(N)=O)N1C(=O)CCC1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA3 P07451 1/20 0.37
CA4 P22748 1/20 0.37
CA6 P23280 1/20 0.37
CA5A P35218 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA13 Q8N1Q1 1/20 0.37
CA14 Q9ULX7 1/20 0.37
CA5B Q9Y2D0 1/20 0.37
ALDH1A1 P00352 1/20 0.36
PKM P14618 1/20 0.36
TSHR P16473 1/20 0.33
SLC1A2 P43004 1/20 0.32
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
ATM Q13315 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31723970 0.91 LMNA (0.43) LMNACA12CA1CA2CA3
SCHEMBL23716973 0.77 ALDH1A1 (0.46) CA12CA1CA9ALDH1A1PKM
SCHEMBL9182487 0.76 KMT2A (0.49) LMNACA12CA1CA2CA3
SCHEMBL7166841 0.76 LMNA (0.35) LMNACA12CA1CA2CA3
SCHEMBL2425269 0.76 LMNA (0.35) LMNACA12CA1CA2CA3
SCHEMBL4950743 0.72 LMNA (0.43) LMNACA12CA1CA2CA3
SCHEMBL31723990 0.70 GSK3A (0.32) LMNAALDH1A1KMT2AMEN1
SCHEMBL1289817 0.69 ALDH1A1 (0.37) LMNACA12CA1CA2CA3
SCHEMBL21820033 0.69 LMNA (0.41) LMNACA12CA1CA2CA3
SCHEMBL7164891 0.69 CYP2D6 (0.33) ALDH1A1PKMSLC1A2KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115329-A1 BIORESORBABLE CROSSLINKED HYDROGELS WITH ENHANCED RADIOPACITY FOR MEDICAL APPLICATIONS BOSTON SCIENTIFIC SCIMED, INC. (US) 2026-04-30 US claimed
US-20250345488-A1 CROSSLINKED HYDROGELS WITH ENHANCED RADIOPACITY FOR MEDICAL APPLICATIONS BOSTON SCIENTIFIC SCIMED, INC. (US) 2025-11-13 US claimed
WO-2026090380-A1 BIORESORBABLE CROSSLINKED HYDROGELS WITH ENHANCED RADIOPACITY FOR MEDICAL APPLICATIONS BOSTON SCIENTIFIC SCIMED, INC. (US) 2026-04-30 WO disclosed
US-20260115329-A1 BIORESORBABLE CROSSLINKED HYDROGELS WITH ENHANCED RADIOPACITY FOR MEDICAL APPLICATIONS BOSTON SCIENTIFIC SCIMED, INC. (US) 2026-04-30 US disclosed
US-20250345488-A1 CROSSLINKED HYDROGELS WITH ENHANCED RADIOPACITY FOR MEDICAL APPLICATIONS BOSTON SCIENTIFIC SCIMED, INC. (US) 2025-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260115329-A1 BIORESORBABLE CROSSLINKED HYDROGELS WITH ENHANCED RADIOPACITY FOR MEDICAL APPLICATIONS RAD54L, EGFR, ARG1 LMNA 3680/4885CA12 769/4885CA1 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.